Safety and Efficacy of Very High Dose Furosemide Continuous Infusions
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BACKGROUND

EFFICACY RESULTS

• Fluid overload is treated with loop diuretics in patients with heart failure
and in patients with acute kidney injury1,2
• There are sparse data regarding use of very high dose continuous loop
diuretic infusions. In some studies, very high doses were only used in
outlying patients (maximum 160 mg/hour)3, 4
• The use of very high dose furosemide continuous infusions at Thomas
Jefferson University Hospital is a rare practice. These infusions range in
dose from 40-240 mg/hour, with no limitation on the duration

SAFETY RESULTS

Characteristic

n = 22

Age, yrs (mean ± SD)

62 ± 15

Male n (%)

14 (64)

Heart Failure n (%)

15 (68)

AKI n (%)

7 (32)

EF (mean ± SD)
Home Diuretic Dose (mg)
(mean ± SD)

40 ± 21
45 ± 82

• The purpose of this study is to examine the efficacy and safety of very
high dose furosemide continuous infusions

Endpoint

Baseline

24 Hours After
Infusion Initiation

SCr (g/dL)

2.6 (±1.4)

2.8 (±1.3)

p value

48 Hours After
Infusion Initiation

p value

0.65

2.7 (±1.4)

0.367

Electrolyte
Abnormalities

Incidence 48 Hours Prior
to Infusion Initiation

Incidence 48 Hours After
Infusion Initiation

p value

K <3.5 mmol/L

0.29 (±0.46)

0.33 (±0.48)

0.666

Mg <1.5 mEq/L

0.05 (±0.22)

0.00 (±0.00)

0.329

Na <125 mmol/L

0.05 (±0.22)

0.00 (±0.00)

0.329

• Two patients had one incidence of hypotension
• No incidence of ototoxicity

METHODS
• This hospital institutional review board approved retrospective cohort
study included adult patients ≥18 years old who were hospitalized at
Thomas Jefferson University Hospital between April 2017 and January 2019

DISCUSSION
• These data show that very high dose furosemide continuous infusions at
doses of 40-240 mg/hr for durations of up to 171 hours are both efficacious
and safe

Administered a
continuous furosemide
infusion at a dose of ≥40
mg/hr

Excluded: expired or started
RRT* within the first 24
hours of infusion initiation

Included: evaluated at 24
and 48 hours prior to and at
3, 6, 12, 24, and 48 hour
intervals post-infusion

*RRT = renal replacement therapy

Primary Endpoint
Change in 24-hour UOP
Secondary
Efficacy Endpoints
Change in 48-hour UOP
Change in 24-hour body weight
Total furosemide doses
Number of thiazide diuretics
Safety Endpoints:
Acute kidney injury
Hypotension
Electrolyte abnormalities
Ototoxicity

• Descriptive statistics were calculated as mean ± SD and were compared by
using paired sample t-tests

• Prospective, multi-center randomized controlled trials should be done to
further confirm the findings in this study
• The range of infusion doses was 40 mg to 240 mg/hr, with a mean of
98 (±41) mg/hr
• Total furosemide doses were higher after infusion initiation (p < 0.001)
• The range of infusion duration was 5 hours to 161 hours, with a mean
of 43(±36) hours
• Body weight decreased from baseline to 24 hours (p = 0.023).
There was no difference in thiazide diuretic administration (p = 0.419)

CONCLUSION
Very high dose furosemide continuous infusions provide a significant increase in
diuresis without worsening renal function, disturbing electrolytes, or increasing
the risk of ototoxicity
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